ArticleActa neurochirurgica2025
Nicotine replacement therapy during the acute phase of aneurysmal subarachnoid hemorrhage.
Article in Acta neurochirurgica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMany patients who suffer an aneurysmal subarachnoid hemorrhage (aSAH) are active smokers that may experience nicotine withdrawal following hospital admission. Nicotine replacement therapy (NRT) could alleviate abstinence and delirium but may have unwanted side-effects. Cerebral vasospasm (VS) is a feared complication of aSAH that can worsen outcome. The impact of NRT on VS, complications and outcome is still not fully delineated.
methodsRetrospective study using anonymized data from a prospective quality registry. Patients smoking status, age, sex, comorbidities, along with aSAH severity were registered. Smokers were dichotomized into non-NRT and NRT groups depending on whether they had received a nicotine patch or not and subdivided into light smokers (≤ 10 cigarettes/day) and moderate to heavy smokers (> 10 cigarettes/day). We also registered radiological/sonological and clinical VS, delayed cerebral ischemia (DCI) related infarction and other common aSAH complications. Outcome was scored in terms of mortality and modified Rankin Score (mRS) at 90 days.
results495 patients were included; 220 received NRT. NRT was not a predictor of radiological/ultrasonological VS or DCI-related infarction. Poor outcome was more frequent in light smokers when they had received NRT (12.49% vs 29.31%) and their length of hospitalization was longer. Moderate to heavy smokers that had received NRT developed less frequently atrial fibrillation (3.4% vs 11.7%) and their length of stay at the ICU was shorter. There was no difference in thromboembolic or epileptic events, or respiratory failure between groups. There was no difference in smoking cessation at 90 days with or without NRT.
conclusionsNRT had no impact on vasospasm or DCI-related infarction and it did not increase the frequency of complications. It seems advisable to abstain from NRT in light smokers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.